Synthorx Inc., a La Jolla, Calif.-based biotechnology company using synthetic biology to discover and develop novel protein therapeutics, completed a $10m Series B financing.
The round was led by RA Capital Management with participation from existing investors Avalon Ventures and Correlation Ventures. In conjunction with the financing, Andrew Levin, M.D., Ph.D., managing director of RA Capital Management, will join Synthorx’s board of directors.
The company intends to use the funds to develop and scale-up its novel protein therapeutics.
Led by Court R. Turner, president and CEO, Synthorx leverages a genetic alphabet platform that expands the chemical and structural repertoire of protein therapeutics and uncovers new ways to modulate pharmacological properties of biologics. Founded based on discoveries in Dr. Floyd Romesberg’s lab at The Scripps Research Institute, the company is working internally and in collaboration with pharmaceutical companies toward the design and discovery of new drugs for a variety of therapeutic areas.